Trials / Terminated
TerminatedNCT00016692
Safety and Tolerability of Z-100 in Patients With Early HIV Infection
A Phase 1b Multicenter Double-Blind, Placebo-Controlled, Randomized Study on the Safety and Tolerability of Z-100 in Early HIV-1 Infected Patients
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Zeria Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to see if Z-100 (an investigational drug) treatment is safe in HIV patients who have never received treatment for their HIV, who have not been taking highly active antiretroviral therapy (HAART) for at least 8 weeks, or who have been stable on their current first or second HAART regimen for at least 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Z-100 |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2006-04-27
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00016692. Inclusion in this directory is not an endorsement.